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Cholinergic basal forebrain (CBF) nucleus basalis
(NB) neurons display neurofibrillary tangles (NFTs)
during Alzheimer’s disease (AD) progression, yet the
mechanisms underlying this selective vulnerability
are currently unclear. Rac1, a member of the Rho
family of GTPases, may interact with the proapoptotic
pan-neurotrophin receptor p75NTR to induce neuro-
nal cytoskeletal abnormalities in AD NB neurons.
Herein, we examined the expression of Rac1b, a con-
stitutively active splice variant of Rac1, in NB cholin-
ergic neurons during AD progression. CBF tissues
harvested from people who died with a clinical diag-
nosis of no cognitive impairment (NCI), mild cogni-
tive impairment, or AD were immunolabeled for both
p75NTR and Rac1b. Rac1b appeared as cytoplasmic
diffuse granules, loosely aggregated filaments, or
compact spheres in p75NTR-positive NB neurons. Al-
though Rac1b colocalized with tau cytoskeletal mark-
ers, the percentage of p75NTR-immunoreactive neu-
rons expressing Rac1b was significantly increased
only in AD compared with both mild cognitive im-
pairment and NCI. Furthermore, single-cell gene ex-
pression profiling with custom-designed microar-
rays showed down-regulation of caveolin 2, GNB4,
and lipase A in AD Rac1b-positive/p75NTR-labeled
NB neurons compared with Rac1b-negative/p75NTR-
526positive perikarya in NCI. These proteins are in-
volved in Rac1 pathway/cell cycle progression and
lipid metabolism. These data suggest that Rac1b ex-
pression acts as a modulator or transducer of vari-
ous signaling pathways that lead to NFT formation
and membrane dysfunction in a subgroup of CBF
NB neurons in AD. (Am J Pathol 2012, 180:526–540; DOI:
10.1016/j.ajpath.2011.10.027)
Rac1, a member of the Rho family of GTPases, is a
ubiquitous intracellular transducer protein that interacts
with specific effectors (eg, p-21-activated kinase) to me-
diate a diverse array of cellular functions, including cyto-
skeleton remodeling, microtubule stability, gene tran-
scription, and superoxide production.1 Rac1 and related
Rho GTPases regulate the formation, reorganization, and
maturation of neuronal dendrites,2,3 indicating a key role
for these proteins in modulating cellular processes un-
derlying normative brain functions. Conversely, Rac1
dysfunction has been implicated in mental retardation
syndromes3,4 and neurodegenerative diseases, includ-
ing Parkinson’s disease5 and Alzheimer’s disease (AD).6
AD, the most common type of dementia in the elderly,
is clinically characterized by a progressive cognitive de-
cline. The hallmark neuropathologic features of the AD
brain are insoluble extracellular deposits of  amyloid
(A), or amyloid plaques, and neurofibrillary tangles
(NFTs), consisting of abnormal intracellular aggregates
of the cytoskeletal protein, tau.7–9 In addition to these
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linergic basal forebrain (CBF) projection neurons located
within the septal diagonal band complex and the nucleus
basalis of Meynert (NB)10–13 and a loss of choline
acetyltransferase (ChAT; the synthetic enzyme for ace-
tylcholine) in CBF hippocampal and cortical target
fields in late AD.14–18 These cholinergic deficits corre-
late with cognitive decline and disease severity in
AD.19–21 NFTs are found in CBF neurons in the brains
of people who died with a clinical diagnosis of AD22–24
and mild cognitive impairment (MCI),24,25 a putative
prodromal AD stage. However, whether Rac1 expres-
sion is associated with the onset of NFT pathology
within CBF neurons during disease progression re-
mains an open question.
Interestingly, CBF neurons depend on nerve growth
factor (NGF) for their survival, and in vitro studies have
shown that the proapoptotic pan-neurotrophin receptor,
p75NTR, activates Rac1 in a NGF-dependent manner,
which may initiate cytoskeletal abnormalities or apoptotic
signaling in AD.26 Moreover, data derived from in vivo and
in vitro investigations show that A interacts with Rac1 to
induce cytoskeletal changes related to NFT forma-
tion27,28 and that RhoA proteins abnormally accumulate
in NFT-bearing neurons in AD.6 Taken together, these
observations suggest that dysregulation of the Rho
GTPase Rac1 is associated with neuronal cytoskeletal
alterations in AD.
A decade ago, a new isoform of Rac termed Rac1b
was identified in breast and colon cancers.29,30 Rac1b is
a self-activated splicing variant of Rac1 that displays a
19-amino acid (aa) insert from exon 3b that creates a
novel effector-binding site absence in Rac1.29,31 The
presence of these additional 19 aa altered the structure
and activity of Rac1b,32,33 rendering it a constitutively
active variant of Rac1.34 Thus, Rac1b overactivation may
play a prominent role in Rac1-related cellular neurode-
generation. Recently, a transcriptomic profiling technol-
ogy developed by Exonhit35 was used to compare alter-
native RNA splicing events present in frontal cortex from
AD (Braak stage VI) and age-matched healthy controls,
which identified splicing alterations occurring in Rac1 in
AD brain.36 Moreover, in a preliminary report we found
Rac1b immunoreactivity within NFT-bearing p75NTR-pos-
itive NB neurons in end-stage AD.37 However, the poten-
tial role of Rac1b in the development of NFT pathology
within NB neurons during the progression of AD has not
been explored. In the present study, we examined the
spatiotemporal nature of Rac1b expression with respect
to tau epitopes underlying NFT formation within p75NTR-
positive NB neurons in postmortem tissue harvested from
people who died with a clinical diagnosis of no cognitive
impairment (NCI), MCI, or AD. Furthermore, we com-
pared gene expression profiles of Rac1b-immunopositive
(Rac1b) and Rac1b-immunonegative (Rac1b) NB
neurons by laser capture microdissection coupled with
custom-designed microarray analysis to identify targets
of potential Rac1b-mediated mechanisms of neurode-
generation in AD.Materials and Methods
Alternative RNA Splicing for Rac1 in AD Brain
and Other Tissues
Expression profiling technology developed by ExonHit
(Paris, France)35 was used to compare alternative RNA
splicing events present in Rac1 within frozen brain tis-
sues accrued from frontal cortex (Brodmann area 9) from
Braak stage VI AD and nondemented healthy controls
both 70 years old. RT-PCR technology determined Rac1b
expression levels in different tissues, including brain.29
The primers used were F1, 5=-ATGCAGGCCATCAAGT-
GTGTGG-3=; R1, 5=-TGGCATTGAGTGCGAAGGC-3=;
and F2, 5=-AAAGACAAGCCGATTGCCG-3=. A discrete
band representing a 492-bp amplicon that corresponds
to the expected size of the Rac1b amplicon was detected
in the brain samples. The amplicon was cloned into Topo
TA cloning vector (Invitrogen, Paris, France) and se-
quenced with SP6 and T7 primers to confirm the se-
quence identity of the Rac1b amplification product.
Generation and Specificity of a Rac1b Antibody
Generation of the Rac1b Antibody
An anti-Rac1b serum (SG-4088) was produced by
Sigma-Genosys (Sigma-Aldrich, St. Louis, MO) accord-
ing to their standard immunization protocol by coupling
the peptide VGETYGKDITSRGKDKPIAC from AD frontal
cortex to keyhole limpet hemocyanin. Serum was then
affinity-purified on a Sepharose column with the use of
the immunogen as bait.
Specificity of the Rac1b Antibody
Ten nanograms of either recombinant Rac1 or Rac1b
[glutathione S-transferase (GST)-tagged; 50 kDa each;
Cytoskeleton, Denver, CO] was separated by electropho-
resis in a 12% SDS-PAGE system and transferred to
Hybond-C membranes (Amersham Biosciences, Paris,
France). After transfer, membranes were blocked with
5% nonfat milk in 0.1% PBS/0.1% Tween-20 and incu-
bated overnight with the primary rabbit anti-Rac1b anti-
body SG-4088 at a 1:5000 dilution, or with a mouse
monoclonal anti-Rac1 antibody ARC03 (1:5000; Cyto-
skeleton, Denver, CO). Immunologic complexes were de-
veloped with an anti-rabbit or an anti-mouse peroxidase
antibody (1:5000; Jackson Laboratories, Paris, France)
followed by enhanced chemiluminescence (Amersham
Biosciences, Paris, France).
Cell Culture and Immunoblot Analysis
Myc (alias c-myc)-tagged Rac1b was cloned into the
NIT tet off-expression vector,38 kindly provided by Dr.
Fred H. Gage (The Salk Institute, La Jolla, CA). NIH3T3
cells (LGC PromoChem, Molsheim, France) were grown
in high-glucose Dulbecco’s modified Eagle’s medium
plus Glutamax supplemented with 10% newborn serum
and antibiotics. NIH3T3 cells were transiently transfected
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doses of doxycycline (Sigma-Aldrich). Forty-eight hours
after transfection, cells were lysed and 7.5 g of protein
was separated on a 12% SDS-PAGE gel and transferred
to Hybond-C membranes (Amersham Biosciences). After
transfer, membranes were blocked with 5% nonfat milk in
0.1% PBS/0.1% Tween-20 and incubated overnight with
the anti-Rac1b antibody at 1:5000, allowing for the de-
tection of both endogenous and Myc-tagged Rac1b. The
membrane was then stripped at 55°C for 20 minutes and
reprobed with an anti-Myc monoclonal antibody at 1:750
(Tebu, Le Perray en Yvelines, France). Immunologic com-
plexes were shown with anti-rabbit or an anti-mouse IgG
(1:5000; Jackson Laboratories) followed by chemilumi-
nescence (Amersham Biosciences).
Cell Culture and Immunocytochemistry
Human embryonic kidney (HEK) 293 cells were main-
tained in modified Eagle’s medium plus Earle’s salt sup-
plemented with 10% fetal bovine serum, 2 mmol/L L-glu-
tamine (Sigma-Aldrich), nonessential amino acids, and
antibiotics. 2  105 HEK293 cells/well were seeded in
6-well plates for 24 hours and transiently transfected with
the Myc-tagged Rac1b expression vector or empty vec-
tor with the use of Lipofectamine Plus (Invitrogen). Forty-
eight hours after transfection, cells were fixed with 4%
paraformaldehyde in PBS, permeabilized with 0.1% Tri-
ton X-100, saturated in 5% nonfat milk/1% bovine serum
albumin, and processed for Rac1b fluorescence immu-
nohistochemistry (SG-4088, 1:500).
Brain Tissue Accrual
The Human Investigations Committee of Rush University
Medical Center and Northwestern University School of
Medicine approved tissue usage for this study. Postmor-
tem tissue containing the CBF neurons of the NB was
harvested from 28 participants in the Religious Orders
Study,39–42 a longitudinal clinical pathologic study of ag-
ing and AD in older Catholic nuns, priests, and brothers
conducted by Rush University Medical Center (Chicago,
IL). Subjects were clinically characterized within a year of
death as having NCI (n  12), MCI (n  8, 6 with nonam-
nestic MCI and 2 with amnestic MCI), and mild AD (n 
7). All MCI and AD cases were evaluated clinically and
pathologically as described previously.43–49 Cortical tis-
sue was also harvested from four NCI, MCI, and AD
cases to test the specificity of the Rac1b antibody.
In addition, brain tissue from 8 cases neuropathologi-
cally characterized as severe (end-stage) AD, based on
Braak stage, were accessed from the Rush Alzheimer’s
Disease Brain Bank. A summary of the clinical and neu-
ropathologic demographics of the cases examined in this
study is shown in Table 1. To test for disease specificity
of Rac1b immunolabeling within CBF neurons of the NB,
we examined tissue harvested from two other tauopa-
thies: Lewy Body disease (LBD; n  4) and frontotempo-
ral dementia (FTD; n  3) (see Table 2) accrued from
Northwestern University School of Medicine (Chicago,
IL). Consensus criteria incorporated into the proceduresof the Uniform Data Set of the NIA Alzheimer’s Disease
Centers program50,51 were used for the clinical diagnosis
of FTD. Pathologic diagnosis of frontotemporal lobar de-
generation (FTLD) and specification of its variants were
rendered according to the published consensus criteria
set forth by the Consortium for FTLD.52 All tissue samples
were fixed at autopsy in 4% paraformaldehyde, cryopro-
tected, and cut at 40 m on a freezing sliding microtome
for immunohistochemical and gene expression analyses
as reported previously.43,44,53
Antibody Characterization
Antibodies used to detect cholinergic neurons of the NB
included a mouse monoclonal antibody generated
against p75NTR (epitope aa 1 to 160) derived from A875
melanoma cells (clone NGFR5; LabVision, Fremont, CA),
which is an excellent marker of CBF neurons in the human
healthy aged and AD brain54,55 and a goat polyclonal an-
tiserum to ChAT (Millipore, Billerica, MA), which specifically
marks cholinergic neurons in human brain.56–58 These an-
tibodies were used in colocalization experiments with
Rac1b and tau-specific epitope markers for NFTs. Antibody
specificity of each cholinergic marker was reported by their
manufacturers.
The tau antibodies used in this study included Alz50, a
mouse monoclonal antibody (gift from Dr. P. Davies, Al-
bert Einstein School of Medicine, Bronx, NY), which
shows an early-stage conformational tau epitope (aa 5 to
15, 312 to 322) and marks neurons undergoing early
degenerative events associated with NFT formation,59–61
AT180 mouse monoclonal antibody (ThermoFisher, Pitts-
burgh, PA), which detects tau phosphorylation at the thre-
onine 231 site, an early event in the disassembly of tau,62,63
and the AT8 mouse monoclonal antibody (ThermoFisher),
which marks tau phosphorylation at both serine 202 and
threonine 205 sites.64 The specificity of the tau antibodies
has been reported by numerous investigators59–64 and
by their manufacturers.
Immunoblot and Immunohistochemistry
Cortical samples from NCI (n  4) and severe AD (n  4)
were processed for Western blot analysis as reported
previously.65 Briefly, tissue was sonicated in ice-cold ho-
mogenization buffer (20 mmol/L Tris, 1 mmol/L EGTA, 1
mmol/L EDTA, 10% sucrose, pH 7.4) containing protease
inhibitors, and protein concentration of S1 fraction was
determined by the Bradford method (Bio-Rad, Hercules,
CA). Sample proteins (48 g/sample) were separated by
SDS-PAGE (7.5% acrylamide) and transferred electro-
phoretically to polyvinylidene fluoride membranes (Immo-
bilon P; Millipore). Membrane was incubated overnight
with rabbit anti-Rac1b antiserum (our SG-4088; 1:1000)
and developed with a horseradish peroxidase-conju-
gated goat anti-rabbit IgG (1:5000; Bio-Rad). Immunore-
active proteins were visualized by enhanced chemilumi-
nescence (Amersham Biosciences) on a Kodak Image
Station 440CF (Eastman Kodak, Cincinnati, Ohio).
Floating sections containing the NB region of the basal
forebrain extending from the decussation of the anterior
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caudally, were dual immunolabeled for p75NTR (1:15,000)
and the polyclonal rabbit Rac1b-specific antibody (1:
1000) with the use of tissue sections from NCI, MCI,
mild/moderate AD, severe AD, LBD, or FTD cases. Sec-
tions were washed several times in Tris-buffered saline
(TBS) before incubation with 0.1 mol/L sodium periodate
(to inhibit endogenous peroxidase activity) in a TBS so-
lution for 20 minutes. After several rinses in a solution
containing 0.25% Triton X-100 in TBS, the tissue was
placed in a blocking solution containing TBS with 0.25%
Triton X-100 and 3% goat serum for 1 hour. Sections were
subsequently incubated in rabbit anti-Rac1b antibody for
24 hours in a medium containing TBS 0.25% Triton X-100
and 1% goat normal serum. After washes with 1% goat
normal serum in TBS, sections were incubated with bio-
tinylated goat anti-rabbit (Vector Laboratories, Burlin-
game, CA) for 1 hour. After several washes in TBS the
tissue was incubated for 60 minutes with an avidin-biotin
complex (1:500; “Elite Kit”; Vector Laboratories). Tissue
was rinsed in 0.2 mol/L sodium acetate, 1.0 mol/L imida-
zole buffer (pH 7.4), and developed in an acetate-imida-
zole buffer containing 2.5% nickel sulfate, 0.05% 3,3=-
diaminobenzidine tetrahydrochochloride (Sigma-Aldrich)
and 0.0015% H2O2. The reaction was terminated with an
acetate-imidazole buffer solution. Subsequently, and af-
ter several washes in TBS, sections were incubated with
anti-p75NTR antibody for 24 hours in a medium containing
TBS 0.25% Triton X-100 and 1% goat normal serum, and
then incubated with biotinylated goat anti-mouse (Vector
Laboratories) and visualized with the chromogen 3,3=-
diaminobenzidine tetrahydrochochloride (brown) without
nickel intensification following the above protocol. This
dual staining resulted in an easily identifiable two-colored
profile: dark blue/black for Rac1b and brown for p75NTR-
positive profiles.54 Bright-field images were acquired with
Nikon microphot microscope (Nikon, Melville, NY). Addi-
tional sections were either double or triple immunofluo-
rescence labeled with the use of antibodies directed
against Rac1b (1:100; SG-4088), ChAT (1:100), the early
conformational tau antibody Alz50 (1:4000), and the tau
phosphorylation antibodies AT180 (1: 300) and AT8 (1:
100). Fluorescence signals were shown with Cy3-, Cy2-,
and Cy5-conjugated anti-mouse, rabbit, and goat IgGs
(Jackson Immunoresearch, West Grove, PA), depending
on the primary antibody. Double and triple immunofluo-
rescence images were acquired and analyzed with a
Zeiss Axioplan 2 (Zeiss, Thorndale, NY) and an Olympus
confocal microscope equipped with FluoroView 4.3 soft-
ware (Olympus, Center Valley, PA), respectively. Omis-
sion of primary antibodies resulted in a lack of immuno-
reactivity in tissue sections. To test the specificity of
Rac1b antiserum the antibody was preabsorbed against
purified Rac1b protein (0.1 mg/mL), followed by immu-
nostaining of NB tissue with the above protocol. Further-
more, to test for the possible cross-reactivity between the
tau antibodies and Rac1b, AT8 (1:1000) and Alz50 (1:
10,000) were preabsorbed with Rac1b protein (0.1 mg/
mL) overnight, followed by our standard immunostaining
protocols. Preabsorption with the Rac1b protein did not
prevent AT8 or Alz50 immunoreactivity.Cell Distribution and Quantitation
The distribution of NB neurons single- and double-
stained for Rac1b and p75NTR receptor were charted with
Neurolucida 8 (MicroBrightField Inc., Williston, VT) with
the aid of Nikon Optiphot-2 microscope. Counts of single
p75NTR and double Rac1b/p75NTR-immunoreactive (ir)
cholinergic NB neurons were performed manually at
magnification of40, and fiduciary landmarks were used
to prevent repeat counting of neurons. The number of
sections counted per case ranged from 6 to 11. Stereo-
logic counting procedures were not used because the
total number of neurons per region was not a requirement
and the tissue was not prepared for unbiased counting.
The results are presented as the percentage of Rac1b/
p75NTR-immunopositive total neurons rather than abso-
lute numbers of cell counts.
Single-Cell Gene Expression Analysis
Immunolabeled p75NTR-positive NB neurons (n  140)
from NCI cases (n  6) and immunolabeled p75NTR and
double-labeled Rac1b/p75NTR NB neurons (n  260) from
severe AD cases (n  7) were accessed by laser capture
microdissection (Arcturus XT; Applied Biosystems). Be-
cause dual Rac1b/p75NTR CBF labeling was negligible in
the MCI cases, gene expression comparisons were not
performed. The amplification of mRNA from individual neu-
rons was performed with terminal continuation RNA ampli-
fication methodology as previously described.39–42,53 Ter-
minal continuation RNA amplification is a linear amplification
process that preserves the original quantitative relation-
ships among the transcripts.39,53,66,67 Hybridization probes
were synthesized by in vitro transcription with the use of 33P
incorporation in 40 mmol/L Tris (pH 7.5); 6 mmol/L MgCl2;
10 mmol/L NaCl; 2 mmol/L spermidine; 2.5 mmol/L DTT;
125 mol/L ATP, GTP, and CTP; 2.5 mol/L cold UTP; 20
U of RNase inhibitor; 2 kU of T7 RNA polymerase (Epi-
center, Madison, WI); and 120 Ci of 33P-UTP (Perkin-
Elmer, Boston, MA).68 The labeling reaction was per-
formed at 37°C for 4 hours. Radiolabeled terminal
continuation RNA probes were hybridized to custom-de-
signed microarrays without further purification.
Custom-Designed Microarray Platforms
Array platforms consist of 1 g of linearized cDNA puri-
fied from plasmid preparations adhered to high-density
nitrocellulose (Hybond XL; GE Healthcare, Piscataway,
NJ) with the use of an arrayer robot (VersArray; Bio-
Rad).39,68,69 Each cDNA and/or EST is verified by se-
quence analysis and restriction digestion. Approximately
576 cDNAs/ESTs are used on the array platform (see
Supplemental Table S1 at http://ajp.amjpathol.org). Ar-
rays were hybridized for 24 hours, washed with serial
dilutions of saline sodium citrate buffer, and then placed
in a phosphor screen for 24 hours before development on
a phosphor imager with ImageQuant 5.2 software (GE
Healthcare).
Hybridization signal intensity of the empty vector (pBS;
double spotted on the array) identified background ac-
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RNA bound to each linearized cDNA was expressed as a
ratio of the total hybridization signal intensity of the array (ie,
global normalization),39,69–72 thereby minimizing variations
because of differences in the specific activity of the probe
and the absolute quantity of the probe present.73–75
Statistical Analysis
Demographic, clinical, and neuropathologic characteris-
tics were compared across clinical diagnostic groups
with one-way analysis of variance, Kruskal-Wallis or Fish-
er’s exact test follow by Dunn’s post hoc test for multiple
comparisons (Sigma Stat 3.5; Systat Software, Inc., San
Jose, CA). Cell count data were analyzed with Kruskal-
Wallis analysis of variance on ranks followed by Dunn’s
method for multiple comparisons, and correlations were
performed with Spearman rank (Sigma Stat 3.5; Systat
Software, Inc.). Single-cell gene array data were ana-
lyzed with GeneLinker 4.6 bioinformatics software with
the use of a false discovery rate controlling proce-
dure68,76 to reduce type I error (IOS, Kingston, ON).
Levels of individual mRNAs were compared among NCI
p75NTR, AD p75NTR, and AD Rac1b/p75NTR with the use
of one-way analysis of variance with post hoc Holm-Sidak
testing for multiple comparisons (Sigma Stat 3.5, Systat
Table 1. Count Analysis: Clinical, Demographic, and Neuropatho
Clinical
NCI (n  12) MCI (n  8)
No. of females (%) 7 (84) 3 (35)
Age at death (years)
Mean  SD 85.9 4.7 86.7  5.3
Range 78.3–92.7 79.4–93.9
Postmortem intervals (hours)
Mean  SD 5.5  2.1 6.6  3.4
Range 3.0–9.7 2–11.5
Brain weight (g)
Mean  SD 1159.9 86.5 1233.7  112.8
Range 1000–1300 1060–1350
No. with ApoE e4 allele (%) 1 (8.3) 4 (50)
Age during education
(years)
Mean  SD 18 3.0 17.8  2.9
Range 10–21 12–20
MMSE score
Mean  SD 28.1 1.4 26.7  2.1
Range 26–28 22–27
Braak stage
0 0 0
I–II 3 1
III–IV 8 7
V–VI 1 0
National Institute on Aging
Reagan
No AD 0 0
Low 6 4
Intermediate 6 4
High 0 0
Six of the eight patients with MCI were non-amnestic.
*Fisher’s exact test.
†One-way analysis of variance.
‡Kruskal-Wallis test.
AD, Alzheimer’s disease; MCI, mild cognitive impairment; NA, not available;Software, Inc.). Descriptive statistical level of significance
was set at 0.05 (two-tailed).
Results
Subject Demographics
The portion of the study that evaluated Rac1b during the
progression of AD included 36 subjects divided into four
clinical diagnostic groups: 12 NCI, 8 MCI, 7 mild/moder-
ate AD, and 8 severe AD (Table 1). No difference was
found for age, sex, postmortem interval, brain weight,
years of education, or Braak scores across groups. The
apolipoprotein E4 allele was most frequent in mild AD
compared with NCI cases (P  0.05). Mini Mental State
Examination scores were significantly lower in mild AD
than in NCI (P  0.05). Mini Mental State Examination
scores were not available for the severe AD cases. NIA
Reagan likelihood of AD scores was significantly higher
in severe AD than in NCI and MCI (Table 1). We also
evaluated three male and one female LBD cases with a
mean age of 79.2 years, and an average postmortem
interval of 7 hours as well as one male familial FTDLD-
fused in sarcoma protein (FUS) and 1 male and 1 female
case of FTLD-TAR DNA-binding protein 43 (TDP) with a
haracteristics by Diagnosis Category
sis
ild AD
 7)
Severe AD
(n  8) P values Pair-wise comparison
71) 6 (75) NS* 
7  6.0 82.5 7.4 NS† 
3–94.5 67–92
8 2.8 7.6 4.0 NS† 
5–8.1 3.3–16
4  138.7 1118.1  147.9 NS† 
0–1460 940–1325
57.51) NA 0.038* NCI  AD
7 3.6 NA NS† 
6–26
2  6.4 NA 0.010‡ NCI  AD
0–28
0 0 NS† 
1 0
3 6
3 2
0 0 0.001‡ NCI, MCI  severe AD
1 0
4 0
2 8logic C
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M
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5 (
8
76.
4.
1.
1226.
106
4 (
19.
1
20.
1NCI, no cognitive impairment; NS, not significant.
oral lob
rotein in
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val of 12 hours (Table 2).
Generation and Characterization of Rac1b
Antibody
Expression profiling showed a dysregulation of the splic-
ing of exon 3b of the Rac1 gene (Figure 1A), leading to
overexpression of the Rac1b isoform in AD compared
with age-matched control cortical brain tissue. Specifi-
cally, the Rac1b isoform displayed 19 aa insert from exon
3b, which is not present in Rac1 (Figure 1A). RT-PCR
analyses showed Rac1b transcripts in specific normal
Table 2. Demographic and Clinicopathologic Characteristics for
Age (years) Sex
LBD/pathologic diagnosis
LBD 82 M
LBD 82 M
LBD 81 M
LBD 72 F
Mean  SD 79.2  4.8
FTD/pathologic diagnosis
FTDLD-FUS (familial) 64 M
FTLD-TDP 67 M
FTLD-TDP 46 F
Mean  SD 59  11.3
F, female; M, male; FTD, frontotemporal dementia; FTLD, frontotemp
disease; NB, nucleus basalis; PMI, postmortem interval; TDP, ubiquitin p
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Figure 1. A: Schematic representations of Rac1 and RAc1b mRNAs showing
an extra exon (3b) in Rac1b and the locations of promoters used in RT-PCR.
B: Agarose gels showing the levels of PCR products for Rac1 (F1/R1), Rac1b
(F2/R1), and actin from heart, liver, brain (normal human frontal cortex),
placenta, spleen, small intestine, colon, MCF-7 (human breast adenocarci-
noma cell line), MDA MB 231 (breast cancer), renal cancer, and prostate
cancer.body tissues (eg, heart, liver, placenta, and spleen) and
cancer tissues [including MCF-7, a human breast ade-
nocarcinoma cell line, and MDA MB 231 (breast, renal,
and prostate cancer cells], whereas Rac1 transcripts
were also detected in normal human frontal cortex, small
intestine, and colon (Figure 1B). Interestingly, this alter-
native splicing of Rac1 was virtually undetectable within
prefrontal cortex from human healthy controls (Figure
1B). Immunoblot analysis showed that the Rac1b antise-
rum (SG-4088) did not cross-react with Rac1, whereas
the commercial anti-Rac1 antiserum (ARC03) recognized
Rac1b protein (Figure 2A). Rac1b cDNA was cloned into
NIT tet off vector and transfected into NIH3T3 cells to test
the specificity of the antibody (SG-4088) generated
against the Rac1b isoform. Immunoblotting showed that
the Rac1b antibody detected the expression of the
Rac1b vector in NIH3T3 cells cultured in the presence of
lower levels or the absence of doxycycline, as expected
(Figure 2B). Notably, this antibody recognized endoge-
nous Rac1b expression in NIH3T3 cells (Figure 2B). Like-
wise, HEK293 cells (Figure 2C) were immunopositive for
Rac1b after 48 hours of transfection with a vector con-
taining Rac1b cDNA (Figure 2D), whereas HEK293 cells
transfected with empty vector were immunonegative (Fig-
ure 2, E and F). Moreover, immunoblotting showed that
the Rac1b antiserum indicated the presence of Rac1b
protein in the cortex of patients with AD, whereas no
immunoreactivity was seen in the cortex of normal human
controls (Figure 3A). These results indicated that the an-
tiserum generated against Rac1b does not cross-react
with Rac1 protein and thus specifically recognizes the
Rac1b isoform in immunoblotting and immunocytochem-
ical procedures.
General Characteristics of Rac1b
Immunostaining in the NB
The immunohistochemical specificity of the Rac1b anti-
serum in the NB was determined by pre-absorption with
the Rac1b protein, resulting in a lack of immunoreactive
profiles within the NB (Figure 3B) compared with neurons
dually immunostained for Rac1b and p75NTR without pre-
d FTD
PMI (hours) Brain weight (g) Rac1b/p75 NB
4 1120 
8 1240 
6 1360 
10 1220 
7  2.5 1235 98.4
13 1210 
9 1330 
14 1150 
12 91.6
ar degeneration; FUS, FTD fused in sarcoma protein; LBD, Lewy body
clusions.LBD anabsorption (Figure 3C).
and the absence of immunostaining for Rac1b (F), respectively. Original
magnification, 10.
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Rac1b immunoreactivity in the NB during the progression
of AD, tissue from each clinical group was double immu-
nostained for Rac1b and p75NTR. Although most of the
Rac1b-ir neurons also displayed p75NTR, not all p75NTR
co-expressed Rac1b (Figure 3C). Rac1b/p75NTR-posi-
tive NB neurons were more frequent in mild and severe
AD cases (Figure 4, A–D), displaying a homogenous
distribution throughout the entire extent of the NB that
included its anteromedial (Ch4am), anterolateral (Ch4al),
intermediate (Ch4i), and posterior (Ch4p)11,54,56 portions
(Figure 5, A–F; see also Supplemental Figures S1–S4 at
http://ajp.amjpathol.org). Rac1b within both single- and
dual-stained NB neurons appeared either as cytoplasmic
granules (Figure 5H), filaments (Figure 5, I and J), or as a
dense compact accumulation of filaments displacing the
nucleus to the periphery of the cell (Figure 5K). In addi-
tion, spheroids of twisted Rac1b-positive filaments were
also seen in the region of the NB (Figure 5L). These
different Rac1b-immunostained profiles were mainly ob-
served in mild AD and severe AD and resembled the
cytoskeletal abnormalities described within the NB with
the use of the pretangle marker AT8 during NFT forma-
tion.23 Rac1b-positive cells with an NFT-like profile as
well as neuropil threads and dystrophic neurites (data not
shown) were also seen in the cortex of mild and severe
AD cases (Figure 5G) but not in NCI or MCI cortex (data
not shown). Pre-absorption with the Rac1b protein did not
block immunoreactivity for AT8 or Alz50-ir within the NB
(Figure 5, M and N), suggesting that these tau antibodies
did not cross-react with Rac1b. In the other tauopathies
examined, only two LBD (Figure 5O) and two FTD (Figure
5P) cases showed dual immunostaining for p75NTR and
50 kDa
NCI AD
Cortex
Anti-Rac1b  
B
A
C
Figure 3. A: Representative immunoblot of cortical samples from a NCI and
a severe AD case probed with our generated antibody against Rac1b (SG-
4088). B: Bright-field image showing the lack of Rac1b immunolabeling in
NB neurons after pre-adsorption of the anti-Rac1b antibody (SG-4088) with
Rac1b protein. C: Bright-field image of double-immunolabeled Rac1b
(black)/p75NTR (brown) and single-labeled p75NTR (brown, black arrow)
NB neurons in an AD case. Inset shows higher magnification of a Rac1b/
p75NTR neuron shown in panel C (open arrow). Scale bars: 30 m (B and
C); 20 m (inset).Rac1
Anti-Rac1b Anti-Rac1 
Rac1b Rac1 Rac1b
50 kDa 
Anti-Rac1b
c-myc-Rac1b
Endogenous-Rac1b
Anti cm c- y
C D
E F
A
B
Figure 2. A: Representative immunoblots of recombinant Rac1b and Rac1
(50 kDa) proteins probed with our generated antibody against Rac1b
(SG-4088; left) and with a commercial antibody against Rac1 (ARC03;
right). Note that Rac1b antiserum (SG-4088) specifically recognized
Rac1b protein and did not cross-react with Rac1, whereas the commercial
Rac1 antibody cross-reacted with Rac1b protein. B: Immunoblot from
NIH3T3 cell cultures transfected with Myc-tagged Rac1b into the NIT tet
off expression vector in the absence (-) or presence of different doses of
doxycycline (dox) probed with anti-Rac1b and anti-Myc antibodies. The
bands from NIH3T3 cells cultured with the lowest concentration (0.2 pg)
or absence of dox showed the highest Rac1b-ir band, which was con-
firmed by reprobing the blots with the antibody against Myc. Rac1b
antiserum also recognized endogenous Rac1b expression in NIH3T3 cells
that was not shown with the Myc antibody. C and E: Contrast-phase
images of HEK293 cells with Myc-tagged Rac1b vector (C) or empty vector
(E), showing the overall cell culture appearance. D and F: Immunofluo-
rescence images of C and E panels, showing Rac1b positive cells (red; D)Rac1b in NB neurons (Table 2).
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AJP February 2012, Vol. 180, No. 2Figure 4. Schematics showing the distribution of neurons either dual stained for Rac1b/p75NTR (red-brown) and singly for p75NTR (green) at similar
anteromedial (Ch4am) and anterolateral (Ch4al) levels of the NB in subjects with NCI (A), MCI (B), mild AD (C), and severe AD (D). The specific
topographic level of the basal forebrain is depicted in the small coronal drawings seen to the right. Note the increase in double-labeled Rac1b/p75NTR
neurons in Ch4am and Ch4al NB portions in mild and severe AD compared with NCI and MCI. Each square represents a single cell. ac, anterior commissure;
AMG, amygdala; Ch4al, cholinergic anterolateral NB portion; Ch4am, cholinergic anteromedial NB portion; Ch4id, cholinergic intermediate-dorsal NB
portion; Ch4iv, cholinergic intermediate-ventral NB portion; Fx, fornix; GPe, external globus pallidus; GPi, internal globus pallidus; ic, internal capsule; Put,
putamen nucleus.
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Immunoreactivity within NB Neurons
To evaluate whether Rac1b profiles co-expressed differ-
ent tau isoforms in NB neurons during the course of AD,
immunofluorescence staining of Rac1b and selected tau
CA B D
 
FE
JH I
N
C
O P
L Mepitopes was performed with the use of tissue from eachof the groups examined in this study (Figure 6, A–I).
Virtually all Rac1b neurons colocalized with AT8, AT180,
and Alz50 immunoreactivity in the NB during AD progres-
sion (Figure 6, A–I). However, only an occasional single
Rac1b-ir neuron was observed in AD (Figure 6, C and I).
Rac1b-ir neurons expressing Alz50 and AT8 were seen
G
Figure 5. A. Bright-field image of double-immu-
nolabeled Rac1b (black)/p75NTR (brown) and sin-
gle-labeled p75NTR (brown) neurons in the antero-
medial portion (Ch4am) of NB from a severe AD
case; inset shows double Rac1b/p75NTR and sin-
gle p75NTR neurons from panel A (arrow). The
specific level of Ch4am is depicted in the schematic
drawing shown in panel B. C: Low-power image
of double-immunolabeled Rac1b (black)/p75NTR
(brown) and single-labeled p75NTR (brown) neu-
rons in the anterolateral portion (Ch4al) of the NB
from a severe AD case; inset shows a double
Rac1b/p75NTR neuron from panel C (arrow). The
specific level Ch4al is depicted in the schematic
drawing shown in panel D. E: Image showing
double-immunolabeled Rac1b (black)/p75NTR
(brown) and single-labeled p75NTR (brown) neu-
rons in the dorsal intermediate NB portion (Ch4id)
of severe AD. The specific level of the dorsal-
intermediate NB subfield is depicted in the sche-
matic drawing in panel F. G: Rac1b-ir cells with an
NFT-like prolife in the temporal cortex of a severe
AD case; inset shows a high-power image of a
cortical Rac1b-ir neuron from panel G (arrow).
H–K: High-power images showing subtypes of
neuronal cytoplasmic Rac1b immunoreactivity
(black) in p75NTR-positive (brown) NB neurons
with a granular (H), filamentous (I and J), or com-
pact spherical (K) appearance in severe AD. L:
Twisted Rac1b-positive filaments in the NB in se-
vere AD.M and N: AT8-ir and Alz50-positive neu-
rons and processes in the NB after pre-adsorbing
the AT8 and Alz50 antibodies with Rac1b protein,
respectively, in severe AD, indicating the specific-
ity of the tau antibody staining. O: Bright-field im-
age of double labeling for Rac1b (black) and
p75NTR, showing their colocalization in a neuron
(arrow) as well as single p75NTR neurons (brown)
in NB in a LBD case; inset shows a higher mag-
nification image of a Rac1b/p75NTR neuron from
panel O (arrow). P: Bright-field image showing
double-labeled Rac1b and p75NTR (arrow) and
single-labeled p75NTR (brown) NB neurons in a
FTD case; inset shows a detail of Rac1b/p75NTR-
positive NB neuron shown in panel P (arrow). ac,
anterior commissure; AMG, amygdala; Ch4al, cho-
linergic anterolateral NB portion; Ch4id, cholin-
ergic intermediate-dorsal NB portion; Ch4iv, cho-
linergic intermediate-ventral NB portion; Fx,
fornix; GPe, external globus pallidus; GPi, internal
globus pallidus; ic, internal capsule; Put, putamen
nucleus. Scale bars: 100 m (A and C); 40 m
(inset in A); 120 m (E); 60 m (G); 10 m (H–L,
insets in O and P); 30 m (M–O and inset in C);
20 m (P and inset in G).Kmore often in MCI and AD (Figure 6, B, C, E, and F) than
AD (I) c
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AJP February 2012, Vol. 180, No. 2in NCI cases. In addition, fluorescence triple labeling
showed that a few ChAT-ir neurons displayed Alz50 but
not Rac1b in NCI (Figure 6G) or MCI (Figure 6H) cases.
In contrast, ChAT-ir neurons containing Alz50 also were
reactive for Rac1b in AD (Figure 6I).
Rac1b/p75NTR-ir NB Neuron Number
Increases in AD
Neuronal counts were performed to determine the
number of single p75NTR versus Rac1b/p75NTR-posi-
tive NB neurons across NCI, MCI, mild/moderate AD,
and severe AD cases (Figure 7). Analysis of variance
showed that the percentage of p75NTR-positive neu-
rons expressing Rac1b protein was significantly in-
creased in mild and severe AD than in MCI and NCI
(Figure 7; P  0.05). However, no significant differ-
ences in the percentage of p75NTR-positive neurons
containing Rac1b were detected between mild and
NCI MC
A B
G H
D E
Figure 6. A–C: Immunofluorescence merged images showing dual-labeled
NCI (A), MCI (B), and severe AD (C). Note the increase in single (open arro
case. D–F: Laser confocal merged images of Alz50 (green), AT8 (red), and R
NCI case (D) and triple-labeled Rac1b, Alz50, and AT8 (pink/white, arrows)
of ChAT (red), Alz50 (green), and Rac1b (blue), showing few double-labeled
MCI (H;white arrow), whereas single Rac1b-ir neurons (blue) and triple sta
in the extent of double-labeled Alz50 and ChAT neuropil threads (yellow) in
30 m (F).severe AD or between the MCI and NCI groups (Figure7; P  0.05). No correlations were observed between
the percentage of Rac1b/p75NTR-positive neurons in
the NB and neuropathologic or clinical variables exam-
ined across groups.
AD
C
I
F
ed) and Alz50 (green) NB-positive neurons (orange/yellow) in subjects with
d double (white arrows) Rac1b and Alz50-positive neurons in a severe AD
lue), showing double-labeled Rac1b and Alz50 NB neuron (pale green) in a
rons in MCI (E) and severe AD (F) cases. G–I: Laser confocal merged images
nd ChAT (yellow) process and neurons in NB in NCI (G; white arrow) and
Rac1b, Alz50, and AT8 neuron (white) were seen in AD (I). Note the increase
ompared with MCI (H). Scale bars: 40 m (A, C, D, and E); 50 m (B, G–I);
Figure 7. Bar graph showing the mean values of the percentage of Rac1b/
p75NTR-ir Ch4 NB neurons in NCI, MCI, and mild and severe AD. Statistical
analysis indicated a significant increase in the percentage of double Rac1b/
NTRI
Rac1b (r
ws) an
ac1b (b
NB neu
Alz50 a
ined forp75 -ir in NB neurons in mild and severe AD compared with the NCI and
MCI groups (*P  0.05).
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Rac1b/p75NTR-Positive NB Neurons
Custom-designed microarrays were used to compare
gene expression profiles of p75NTR single or Rac1b/
75NTR double-labeled NB neurons from AD cases in com-
parison to p75NTR-labeled neurons from NCI. Although
relatively few genes displayed alterations across the in-
dividual cell types, significant differences were found in
the expression levels for mRNAs encoding the G protein
 polypeptide 4 (GNB4), fetal Alzheimer antigen (FALZ),
lipase A (LIPA), and caveolin 2 (CAV2) genes (Figure 8;
see also Supplemental Table S1 at http://ajp.amjpathol.
org). Specifically, FALZ levels were significantly reduced
in AD p75NTR compared with NCI p75NTR-positive NB
neurons but not within AD Rac1b/p75NTR NB-labeled
neurons (P  0.05; Figure 8A). By contrast, transcript
levels of GNB4, LIPA, and CAV2 were significantly down-
regulated in AD Rac1b/p75NTR-positive NB neurons
compared with NCI p75NTR-ir NB neurons (P  0.05;
Figure 8, B–D). Moreover, CAV2 mRNA was reduced in
AD Rac1b/p75NTR-positive NB neurons compared with
ADp75NTR-positive NB neurons (Figure 8D; P  0.05).
Discussion
Herein, we provide biochemical, genomic, and morpho-
logic evidence that Rac1b, a constitutively active Rac1
splice variant, accumulates within cholinergic NB neu-
rons during the progression of AD. Rac1b protein expres-
sion within a select group of p75NTR-positive NB neurons
is significantly increased in moderate and severe AD
compared with MCI and NCI cases. These Rac1b/
p75NTR-positive neurons displayed a phenotype compa-
rable to the tau cytoskeletal abnormalities described dur-
ing the progression of NFTs within the NB in AD.23 Single-
cell gene array analysis of Rac1b/p75NTR dual-labeledNB neurons showed a decrease in GNB4, LIPA, and
CAV2 transcripts in AD compared with singly labeled
p75NTR-containing neurons in NCI, suggesting that
Rac1b activity regulates lipid metabolism and cell-cycle
pathways (see below). Hence, these signaling cascades
may be linked to Rac1b-mediated cytoskeletal and mem-
brane dysfunction, resulting in NB NFT pathology and
ultimately neuronal death in advanced AD.
The present study showed that Rac1b was selectively
expressed in a subpopulation of p75NTR-positive cholin-
ergic neurons within the NB in AD. In this regard, the
percentage of the double-labeled Rac1b/p75NTR-ir NB
neurons increased in mild and severe AD compared with
MCI and NCI. Although the functional consequences of
the expression of Rac1b within NB neurons remain un-
known, studies suggest that it may interact with the CBF
neuron survival factor NGF and its receptors. The differ-
entiation, survival, and function of CBF neurons depend
on the binding of NGF to its cognate receptor TrkA77,78
and the pan-neurotrophin receptor p75NTR.79–81 These
receptors are produced in CBF neurons and transported
to their cortical projection sites.81,82 In general, the TrkA
receptor is associated with cell survival, whereas p75NTR
shows a dichotomous role that induces cell survival or
apoptosis, depending on the cellular milieu. Clinical
pathologic studies show that the ratio of TrkA to p75NTR
receptors is decreased during the progression of AD,
suggesting that the NGF system shifts from cell survival
to cell death during disease onset.83 Interestingly, re-
ports indicate that p75NTR-mediated apoptosis requires
the activation of Rac1.26,84 Therefore, the increase in
number of p75NTR-positive NB neurons expressing
Rac1b could be indicative of its involvement in p75NTR-
mediated apoptotic signaling pathways within these cho-
linergic neurons in AD. Although the mechanism whereby
Rac1b expression might promote neurodegeneration is
Figure 8. Linear graphs showing the mean val-
ues of the relative density of fetal Alzheimer
antigen (FALZ) (A), GNB4 (B), LIPA (C), and
CAV2 (D) transcripts in NCI and severe AD ob-
tained from single p75NTR and AD double
Rac1b/p75NTR-positive NB neurons with the
use of single-cell gene array technology. Signif-
icant down-regulation in FALZ mRNA in
p75NTR-ir Ch4 neurons was detected between
NCI and AD (A). In addition, down-regulation of
GNB4 (B), LIPA (C), and CAV2 (D) transcripts in
AD Rac1b/p75NTR neurons compared with NCI
p75NTR-positive NB neurons. Down-regulation
of CAV2 (D) was also found between p75NTR-ir
and Rac1b/p75NTR-positive neurons in severe
AD (*P  0.05).unclear, it has been shown that Rac1b stimulates the
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cycle (G1/S) progression.
85 Indeed, NB neurons display
a greater expression of cell cycle-related proteins such
as cyclin D1 and proliferating cell nuclear antigen in MCI
and AD compared with NCI.86,87 The presence of these
proteins in NB as well as in cortical neurons has been
interpreted as a lethal reentrance into the cell cycle that
promotes an aberrant DNA replication that precedes cel-
lular death.86 Significantly, cell cycle kinases such as
cdc2 have been shown to contribute to tau hyperphos-
phorylation,88 suggesting a role for Rac1b in reactivating
cell cycle progression that contributes to neurofibrillary
degeneration in postmitotic neurons in AD. On the one
hand, the expression of Rac1b in p75NTR NB-positive
neurons may stimulate anti-apoptotic signaling that, in
turn, activates proteins associated with cell survival (such
as Akt) similar to those described for Rac1.34,85 Whether
Rac1b interacts with p75NTR to promote cell death or
survival during the course of AD is an area requiring
continued investigation. On the other hand, the concept
that intraneuronal p75NTR is a necessary precondition for
the induction of Rac1b is not supported by our observa-
tions that cortical neurons also display Rac1b but are
p75NTR immunonegative in AD.
Several lines of evidence suggest that dysregulation of
Rac1 GTPase activity plays a key role in cytoskeletal
perturbations that lead to the formation of NFTs in
AD,6,27,28 particularly within CBF neurons.26 In the pres-
ent study, we observed that Rac1b colocalizes with mark-
ers of NFT formation within the NB cholinergic neurons
mainly in the later stages of the disease. In addition, the
morphologic appearance of Rac1b in NB neurons was
similar to the cytoskeletal changes described with the
AT8 antibody, suggesting that Rac1b participates in the
induction of cytoskeletal alterations related to NFT forma-
tion in AD. Our double/triple labeling experiments
showed that most of the Rac1b-positive neurons in the
NB colocalized with either phosphorylation-dependent
and/or conformational tau markers in AD and to a lesser
extent in MCI. We also found Rac1b-ir cholinergic neu-
rons with the NB in LBD and FTD cases, suggesting that
the expression of Rac1b in NB cholinergic neurons is a
common feature of tauopathies. Perhaps GTPase protein
effectors engage mechanisms related to tau aggrega-
tion/NFT formation and other cytoskeletal-related inclu-
sions such as the FTD fused in sarcoma protein.
Another contributing factor to the putative effects of
Rac1b on NFT formation may be its interactions with A,
which is thought to be a prime agent in the pathogenesis
of AD,89 including NFT formation.90–92 In this regard, we
have found that A stimulates Rac1b recruitment in neu-
rons (unpublished observations, Desire 2008). Moreover,
in the present study we reported that Rac1b-positive
neurons, in areas of the cortex, contain A pathology in
mild and severe AD cases. In vivo and in vitro studies
have shown that A modifies Rac1 activity, causing
changes in filamentous actin cytoskeletal dynamics.27,28
Moreover, abnormal accumulation of filamentous actin
has been associated with tau-induced neurodegenera-
tion in mouse models of tauopathy.93 Although, virtually
no extracellular or intracellular A is present in the regioncontaining the NB,94 we cannot exclude the possibility
that cortical A might induce a retrograde signal, which
activates either Rac1 or Rac1b, resulting in cytoskeletal
alterations underlying NFT formation within CBF neurons.
The present single-cell gene expression profiling ex-
periments showed specific Rac1b-dependent reductions
in genes relevant to cell cycle re-entry (GNB4) and lipid
metabolism (CAV2 and LIPA) in AD p75NTR-positive NB
neurons compared with NCI p75NTR-ir NB neurons. This
gene signature provides a fairly unique expression profile
that has not been observed by our group in other types of
neurons in the NB or in hippocampal tangle-bearing neu-
rons in AD.41,66,75 Because we also found Rac1b-positive
neurons in the AD cortex, it will be interesting to deter-
mine whether these perikarya display a similar gene pro-
file to that found in the NB cholinergic neurons. GNB4 is
a transducer of membrane receptor signaling related to
cell cycle. CAV2 is found in membrane lipid rafts and
plays a role in membrane fluidity, protein trafficking, neu-
rotransmission, and receptor trafficking.95 Dysfunction in
lipid rafts occurs in normal aging and AD95,96 and may
play a key role in the synthesis of A and its oligomer-
ization in AD.97 Although the relationship between CAV2
and Rac1b remains unknown, we speculate that CAV2
plays a role in the regulation of Rac1b in AD. Future
studies will be necessary to determine the role and rela-
tionship between caveolin proteins and Rac in AD. Like-
wise, there was a reduction in LIPA transcript levels in AD
Rac1b/p75NTR compared with NCI p75NTR-positive NB
neurons. This enzyme, which is found in lysosomal mem-
brane compartments, breaks down lipids such as cho-
lesteryl esters and triglycerides, and mutations in LIPA
result in cholesteryl ester storage diseases, such as Wol-
man disease. Taken together, these data suggest that
Rac1b activity involves molecular interactions with path-
ways that regulate lipid metabolism/plasma membrane
maintenance, which potentially contribute to the patho-
physiology seen in AD.98
In summary, our study shows biochemical, genomic,
and morphologic evidence that Rac1b, a constitutively
active Rac1 spliced variant, increases in a subpopulation
of p75NTR-positive NB neurons that colocalize with patho-
logic tau epitopes during the course of AD. Likewise
Rac1b/p75NTR-positive neurons display a significant
down-regulation of GNB4, LIPA, and CAV2 mRNAs in
severe AD. Overall, the present data suggest that in-
creased Rac1b expression acts as a modulator or
transducer of various signaling pathways, including
cell-cycle re-entry and lipid metabolism that leads to
NFT formation and membrane dysfunction in a sub-
group of p75NTR cholinergic NB neurons in AD. Per-
haps, Rac1b inhibitors may be useful to study the
function of this splice variant in AD.33
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